308 related articles for article (PubMed ID: 16740729)
1. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
4. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
[TBL] [Abstract][Full Text] [Related]
5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
6. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses.
Heine A; Grünebach F; Holderried T; Appel S; Weck MM; Dörfel D; Sinzger C; Brossart P
Mol Ther; 2006 Feb; 13(2):280-8. PubMed ID: 16219490
[TBL] [Abstract][Full Text] [Related]
7. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
8. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
11. Impact of transfection with total RNA of K562 cells upon antigen presenting, maturation, and function of human dendritic cells from peripheral blood mononuclear cells.
Gao L; Fan HH; Lu HZ; Nie XX; Liu Y; Yang YM; Qian KC; Gao F
Transfusion; 2007 Feb; 47(2):256-65. PubMed ID: 17302772
[TBL] [Abstract][Full Text] [Related]
12. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
14. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
15. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
[TBL] [Abstract][Full Text] [Related]
16. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
[TBL] [Abstract][Full Text] [Related]
17. Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.
Abu-Eisha HM; Butt NM; Clark RE; Christmas SE
Leuk Res; 2007 Dec; 31(12):1675-81. PubMed ID: 17324459
[TBL] [Abstract][Full Text] [Related]
18. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
[TBL] [Abstract][Full Text] [Related]
19. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
[TBL] [Abstract][Full Text] [Related]
20. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
